UK Markets closed

2022 Outlook on the Emerging Isotopes Industry to 2029 - Featuring Orano Med, Plus Theapeutics and Point Biopharma Global Among Others

·5-min read
Company Logo
Company Logo

Dublin, July 28, 2022 (GLOBE NEWSWIRE) -- The "Emerging Isotopes Pipeline Analysis and Global Market - Forecast To 2029" report has been added to's offering.

This report gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications.

The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

Market Analysis

  • In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.

  • Emerging Isotopes related deals analysis.

  • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).

  • Pipeline Analysis

  • Pipeline Analysis based Isotopes

  • Pipeline Analysis based on indications

  • Pipeline analysis based on targets

  • Pipeline analysis based on leading players

Key Players Analysis

  • The key player's analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

  • Key players overview

  • Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)

  • Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

Key Topics Covered:

1 Executive Summary

2 Introduction

3 Emerging Isotopes
3.1 Introduction
3.2 Pipeline Analysis Overview
3.2.1 Diagnostic Isotopes Pipeline Analysis
3.2.2 Therapeutic Isotopes Pipeline Analysis
3.3 Demand Analysis of Emerging Isotopes
3.4 Lutetium (Lu-177)
3.4.1 Gep-Net Market Analysis
3.4.2 Prostate Cancer Market Analysis
3.4.3 Lutetium Pipeline Analysis Demand and Production Analysis of Lutetium-177 (Lu-177)
3.4.4 Lu-177 - Deals, Approvals, and Funding
3.5 Gallium (Ga-68)
3.5.1 Supply Chain Analysis of Gallium-68 (Ga-68)
3.5.2 Ga-68 Market Characteristics of Current Ge-68/Ga-68 Generators
3.5.3 Gallium-68 (Ga-68) Pipeline Analysis
3.5.4 Ga-68 - Deals, Approvals, and Funding
3.6 Actinium (Ac-225)
3.6.1 Production Analysis of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213)
3.6.2 Actinium (Ac-225) Pipeline Analysis
3.6.3 Ac-225 - Deals, Approvals, and Funding
3.7 Yttrium (Y-90)
3.7.1 Yttrium (Y-90) Pipeline Analysis
3.7.2 Y-90 - Deals, Approvals, and Funding
3.8 Zirconium (Zr-89)
3.8.1 Zirconium (Zr-89) Pipeline Analysis
3.8.2 Zr-89 - Deals, Approvals, and Funding
3.9 Lead (Pb-212)/Bismuth (Bi-212)
3.9.1 Lead (Pb-212) Pipeline Analysis
3.9.2 Pb-212 - Deals, Approvals, and Funding
3.10 Copper (Cu-64)
3.10.1 Copper 64 (Cu-64) Pipeline Analysis
3.10.2 Cu-64 - Deals, Approvals, and Funding
3.11 Copper (Cu-67)
3.11.1 Copper 67 (Cu-67) Pipeline Analysis
3.11.2 Cu-67 - Deals, Approvals, News, and Funding
3.12 Rhenium (Re-186)
3.12.1 Rhenium (Re-186) Pipeline Analysis
3.12.2 Re-186 - Deals, Approvals, News, and Funding
3.13 Rhenium-188 (Re-188)
3.13.1 Rhenium (Re-188) Pipeline Analysis
3.13.2 Re-188 - Deals, Approvals, News, and Funding
3.14 Astatine (At-211)
3.14.1 Astatine (At-211) Pipeline Analysis
3.14.2 At-211 - Deals, Approvals, News, and Funding
3.15 Holmium (Ho-166)
3.15.1 Holmium (Ho-166) Pipeline Analysis
3.15.2 Ho-166 - Deals, Approvals, and News
3.16 Radium (Ra-223)
3.16.1 Supply Chain Analysis of Radium-223 (Ra-223)
3.16.2 Radium (Ra-223) Pipeline Analysis
3.17 Radium (Ra-224)
3.17.1 Radium (Ra-224) Pipeline Analysis
3.17.2 Ra-224 - Deals, Approvals, News, and Funding
3.18 Thorium (Th-227)
3.18.1 Thorium (Th-227) Pipeline Analysis
3.19 Scandium (Sc-43, 44, 47)
3.20 Terbium (Tb-149,152,155, 161)
3.21 Arsenic (As-72, As-74, As-77)
3.22 Iron (Fe-52)
3.23 Barium-128 (Ba-128)
3.24 Barium-131 (Ba-131)

4 Major Player Profiles
4.1 Boston Scientific Corporation (Bsc)
4.2 Clarity Pharmaceuticals Limited
4.3 Curium Sas
4.4 Eckert & Ziegler Strahlen- Und Medizintechnik AG (Pentixapharm, Gmbh)
4.5 Fusion Pharmaceuticals, Inc.
4.6 Itm Isotope Technologies Munich Se
4.7 Novartis AG
4.8 Orano Med, LLC
4.9 Plus Therapeutics, Inc.
4.10 Point Biopharma Global, Inc.
4.11 Radiomedix, Inc.
4.12 Telix Pharmaceuticals, Ltd.

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting